For Quick Alerts
For Daily Alerts

Biocon Shares Hit 52-Week High After DCGI Approves Its Drug For COVID-19 Treatment


On Monday, shares of Biocon Ltd surged as much as 9.8 percent to Rs 446.95, its new 52-week high after the drugmaker announced that it has received an emergency use authorisation (EUA) for its monoclonal antibody Itoliuzumab from the Drug Controller General of India (DCGI) to treat cytokine storms, one of the leading causes of death among patients severely affected by COVID-19.

Biocon Hits 52-Week High After DCGI Approves Its Drug For COVID-19 Treatment

On Saturday, in a stock exchange filing, Biocon said it has received the DCGI's approval to market Itolizumab (ALZUMAbTM) Injection 25mg/5mL solution for emergency use in India for the treatment of cytokine release syndrome (CRS) in moderate to severe ARDS (acute respiratory distress

syndrome) patients due to COVID-19.

"Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with moderate to severe COVID-19 complications. Biocon has repurposed Itolizumab, an anti-CD6 IgG1 monoclonal antibody launched in India in 2013 as ALZUMAbTM for treating chronic plaque psoriasis, for the treatment of CRS in moderate to severe ARDS patients due to COVID-19," it said.

"Itolizumab will be manufactured and formulated as an intravenous injection at Biocon's bio-manufacturing facility at Biocon Park, Bengaluru," it added.

The approval of Itolizumab, from the DCGI is based on the results from the successful conclusion of a randomized, controlled clinical trial at multiple hospitals in Mumbai and New Delhi.

For the March-ended quarter, Biocon reported a 42.3 percent year-on-year decline in its consolidated net profit to Rs 123.40 crore while net sales rose 3.4 percent to Rs 1,581 crore during the period.

Read more about: biocon
Story first published: Monday, July 13, 2020, 15:08 [IST]
Company Search
Get Instant News Updates
Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more